2. Anti-infection Metabolic Enzyme/Protease GPCR/G Protein
  3. Influenza Virus Endogenous Metabolite Free Fatty Acid Receptor
  4. Ginsenoside Rb2

Ginsenoside Rb2  (Synonyms: Ginsenoside C)

Cat. No.: HY-N0040 Purity: 99.87%
COA
SDS
Handling Instructions Technical Support

Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate GPR120 gene expression. Ginsenoside Rb2 has antiviral effects.

For research use only. We do not sell to patients.

CAS No. : 11021-13-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in Water In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Ginsenoside Rb2:

Ginsenoside Rb2 Related Antibodies

Top Publications Citing Use of Products
Cell Imaging/Staining
Cell Proliferation/Viability Assay
RT-PCR
Apoptosis Analysis
WB

    Ginsenoside Rb2 purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2022;45(1):71-76.

    CCK-8 was used to evaluate the proliferation of H9c2 cells treated with Ginsenoside Rb2 (Rb2) (10, 20, 50, 100 μM).

    Ginsenoside Rb2 purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2022;45(1):71-76.

    Cell apoptosis was evaluated by flow cytometry treated with Ginsenoside Rb2 (Rb2).

    Ginsenoside Rb2 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2021 Jun;23(6):415.  [Abstract]

    Micrographs of senescent cells characterized by accumulation of SA-β-gal within cytoplasm (blue staining), and comparisons of the SA-β-gal-positive cells in PDL25 cells with Lv-miR-216a transfection after treatment with or without 10 µM Ginsenoside Rb2 (Rb2).

    Ginsenoside Rb2 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2021 Jun;23(6):415.  [Abstract]

    mRNA expression levels of senescent-related genes p53 and p21 in PDL25 cells transfected with Lv-miR-216a with or without Ginsenoside Rb2 (Rb2) (10 μM) treatment.

    Ginsenoside Rb2 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2021 Jun;23(6):415.  [Abstract]

    Protein expression levels of senescent-related genes p53 and p21 in PDL25 cells transfected with Lv-miR-216a with or without Ginsenoside Rb2 (Rb2) (10 μM) treatment.

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    View All Free Fatty Acid Receptor Isoform Specific Products:

    View All Isoforms
    FFAR1 FFAR2 FFAR3 FFAR4

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate GPR120 gene expression. Ginsenoside Rb2 has antiviral effects.

    IC50 & Target

    GPR120[1]
    Cellular Effect
    Cell Line Type Value Description References
    Hepatocyte IC50
    105 μM
    Compound: 13
    Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
    Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
    		[PMID: 11325227]
    In Vitro

    Ginsenoside Rb2 pre-treatment enhances the anti-inflammatory effect of α-linolenic acid (ALA) and that the enhancing effect is strictly dependent on GPR120 activation. Ginsenoside Rb2 exerts anti-inflammatory effect in lipopolysaccharide (LPS)-stimulated mouse macrophage RAW264.7 cells in vitro by increasing GPR120 expression and subsequently enhancing ω-3 fatty acid-induced GPR120 activation. Ginsenoside Rb2 improves glucose metabolism in hepatocytes by activating AMPK and reduces cholesterol and triacylglycerol levels in 3T3-L1 cells by reducing oxidative damage. Ginsenoside Rb2 exerts anti-apoptosis effects in murine bone marrow-derived mesenchymal stem cells (BMMSCs). MTT assay results show no obvious cytotoxicity of Ginsenoside Rb2 (up to 100 μM) toward RAW264.7 cells in the absence or presence of ALA. The influence of Rb2 on GPR120 expression in RAW264.7 macrophages is investigated by treating the cells with Ginsenoside Rb2 (0.1-100 μM) for 12 h followed by harvesting and lysis. Subsequent Western blot analysis shows that expression of GPR120 is dose-dependently upregulated by Ginsenoside Rb2. Real-time PCR results indicate that incubation of RAW264.7 macrophages with Ginsenoside Rb2 (10 μM) for 12 h leads to a 2.8-fold increase in GPR120 mRNA expression. In addition, this increase in GPR120 expression stimulated by Ginsenoside Rb2 is time dependent and begins as early as 6 h. These results indicate that Rb2 upregulates GPR120 expression in a dose- and time-dependent manner in RAW264.7 macrophages[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ginsenoside Rb2 Related Antibodies
    In Vivo

    Ginsenoside Rb2 is an antiviral reagent to protect against rotavirus (RV) infection. When various dosages of Ginsenoside Rb2 (25 to 250 mg/kg) are administered 3, 2 or 1 days before virus challenge, treatment with this Ginsenoside at the dosage of 75 mg/kg 3 days before virus infection most effectively reduces rotavirus (RV) -induced diarrhea. In addition, consecutive administration of Ginsenoside Rb2 (75 mg/kg) 3, 2, and 1 day before virus infection is more effective than single administration on day-3. The consecutive administration of Ginsenoside Rb2 also reduces virus titers in the bowels of RV-infected mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    1079.27

    Formula

    C53H90O22
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O[C@@](O[C@H](CO)[C@@H](O)[C@@H]4O)([H])[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO)C)(CC[C@@]2([H])C3(C)C)[C@]6([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO[C@H](OC[C@H](O)[C@@H]8O)[C@@H]8O)([H])CC6)C
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : ≥ 100 mg/mL (92.66 mM)

    DMSO : 9.5 mg/mL (8.80 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.9266 mL 4.6328 mL 9.2655 mL
    5 mM 0.1853 mL 0.9266 mL 1.8531 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 0.92 mg/mL (0.85 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.92 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 0.92 mg/mL (0.85 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.92 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (92.66 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.87%

    SDS (392 KB)

    COA (260 KB) HNMR (381 KB) RP-HPLC (261 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    Cell viability is determined using the MTT assay. RAW264.7 cells (2×104 cells/well) are plated in 96-well plates and cultured overnight in growth medium. The cells are then incubated with Ginsenoside Rb2 (0.1, 1, 10 and 100 μM) at the indicated concentrations in the absence or presence of ALA for 48 h before addition of the MTT reagent (0.5 mg/mL). After incubation for 4 h, the medium is removed, and the formazan crystals formed are dissolved with 100 μL DMSO. Absorbance at a wavelength of 492 nm is measured using a FlexStation 3[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    Groups of five BALB/c newborn mice are inoculated p.o. with RV-SA11 (1.5×106 plaque-forming units (PFU)/mouse) and administered p.o. with the indicated doses of Ginsenoside Rb2 on the indicated days. In order to examine the protective effect of Ginsenoside Rb2 on RV infection, newborn mice are treated orally with 75 mg/kg of this Ginsenoside 3, 2 or 1 day before RV infection, and the severity of diarrhea of RV-infected mice i calculated. In addition, in an experiment in which various doses of Ginsenoside Rb2 ranging from 25 to 250 mg/kg are administered to mice 3 days before RV infection, Ginsenoside Rb2 at the dose of 75 mg/kg elicits higher protective activity compared to either of the dose of 25 to 250 mg/kg.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 0.9266 mL 4.6328 mL 9.2655 mL 23.1638 mL
    5 mM 0.1853 mL 0.9266 mL 1.8531 mL 4.6328 mL
    H2O 10 mM 0.0927 mL 0.4633 mL 0.9266 mL 2.3164 mL
    15 mM 0.0618 mL 0.3089 mL 0.6177 mL 1.5443 mL
    20 mM 0.0463 mL 0.2316 mL 0.4633 mL 1.1582 mL
    25 mM 0.0371 mL 0.1853 mL 0.3706 mL 0.9266 mL
    30 mM 0.0309 mL 0.1544 mL 0.3089 mL 0.7721 mL
    40 mM 0.0232 mL 0.1158 mL 0.2316 mL 0.5791 mL
    50 mM 0.0185 mL 0.0927 mL 0.1853 mL 0.4633 mL
    60 mM 0.0154 mL 0.0772 mL 0.1544 mL 0.3861 mL
    80 mM 0.0116 mL 0.0579 mL 0.1158 mL 0.2895 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ginsenoside Rb2 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ginsenoside Rb211021-13-9Ginsenoside CGinsenoside Rb 2Ginsenoside Rb-2Influenza VirusEndogenous MetaboliteFree Fatty Acid ReceptorFFARInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ginsenoside Rb2
    Cat. No.:
    HY-N0040
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB) Italian - IT (392 KB) Korean - KR (392 KB) Portuguese - PT (392 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.